Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNCOPE: Precision Medicine in Rectal Cancer
NCT04842006Recruiting
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2021
- Primary completion
- Aug 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of oxaliplatin in rectal cancer (2 arms), sponsored by Helsinki University Hospital. Primary endpoints: Recurrence-free survival at 5 years and Postoperative circulating tumor DNA at 3 weeks. Started Dec 2021; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04842006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842006.